The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis
- 5 February 2009
- journal article
- Published by Springer Science and Business Media LLC in Acta Diabetologica
- Vol. 46 (2), 145-154
- https://doi.org/10.1007/s00592-008-0090-3
Abstract
Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients from our electronic health record (EHR). We observed no differences in CAD risk among the agents. Metformin was associated with a reduced risk of CHF (HR 0.76, 95% CI 0.64-0.91) and mortality (HR 0.54, 95% CI 0.46-0.64) when compared to sulfonylurea. Pioglitazone was also associated with a lower risk of mortality when compared to sulfonylurea (HR 0.59, 95% CI 0.43-0.81). No other significant differences were found between the oral agents. In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas.Keywords
This publication has 21 references indexed in Scilit:
- Coronary heart disease outcomes in patients receiving antidiabetic agentsPharmacoepidemiology and Drug Safety, 2007
- Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortalityDiabetes/Metabolism Research and Reviews, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metforminDiabetes/Metabolism Research and Reviews, 2006
- Do sulfonylurea drugs increase the risk of cardiac events?CMAJ : Canadian Medical Association Journal, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indicationPharmacoepidemiology and Drug Safety, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998